Charles Schwab Investment Management Inc. Has $842,000 Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Charles Schwab Investment Management Inc. raised its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 10.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 121,356 shares of the company’s stock after purchasing an additional 11,038 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Zevra Therapeutics were worth $842,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of ZVRA. International Assets Investment Management LLC grew its holdings in Zevra Therapeutics by 594.0% in the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock valued at $48,000 after buying an additional 5,940 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after purchasing an additional 2,452 shares during the period. Hunter Associates Investment Management LLC acquired a new stake in Zevra Therapeutics in the 3rd quarter worth $92,000. Intech Investment Management LLC bought a new position in shares of Zevra Therapeutics during the 3rd quarter worth about $95,000. Finally, SG Americas Securities LLC bought a new stake in shares of Zevra Therapeutics in the third quarter valued at about $105,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently weighed in on ZVRA. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, November 20th. JMP Securities assumed coverage on shares of Zevra Therapeutics in a report on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price objective for the company. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Canaccord Genuity Group cut their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Finally, Maxim Group upped their price objective on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $21.00.

Zevra Therapeutics Stock Down 2.2 %

Shares of NASDAQ ZVRA opened at $8.29 on Thursday. The stock has a market cap of $442.49 million, a P/E ratio of -4.21 and a beta of 1.97. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The firm has a 50 day moving average price of $8.71 and a 200 day moving average price of $7.18. Zevra Therapeutics, Inc. has a 52-week low of $4.20 and a 52-week high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The firm had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same quarter last year, the firm earned ($0.40) earnings per share. Analysts expect that Zevra Therapeutics, Inc. will post -1.96 EPS for the current year.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.